• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ethos and Lifeforce Team Up to Help Policyholders Live Longer, Healthier Lives

    8/13/25 8:00:00 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LIFE alert in real time by email

    AUSTIN, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a partnership with Lifeforce, the largest longevity medicine platform. Through this collaboration, Ethos policyholders will be able to gain valuable insights into their own health at affordable prices, starting with a $250 benefit to Lifeforce's Diagnostic offering, that includes at-home biomarker testing, access to board-certified longevity physicians, personalized treatment protocols, and ongoing health coaching. Together, Ethos and Lifeforce aim to help more families safeguard their future - uniting financial protection with longevity care to extend both lifespan and peace of mind.

    Lifeforce was selected as the longevity platform for Ethos customers due to its clinical rigor, white-glove experience, and powerful diagnostic capabilities. With this new benefit, Ethos policyholders will be able to access Lifeforce's platform - enabling them to proactively monitor and improve their health with data-driven insights and professional support.

    Ethos is partnering with best-in-class providers to deliver a curated suite of perks that address policyholders' most important priorities. The perks program complements Ethos' recently launched Indexed Universal Life insurance offering - a wealth-building product with living benefits, tax advantages, and optional retirement income - as well as the company's complimentary estate planning tools. With the addition of Lifeforce, Ethos is now empowering policyholders to not only protect their financial future but also to help extend their healthspan.

    "At Ethos, we believe that protecting your family starts with protecting yourself," said Prassath Leelakrishnan, Chief Growth Officer, Ethos. "Our partnership with Lifeforce gives our policyholders access to longevity care, making it as simple to prioritize your health as it is to plan your financial future. It's a powerful combination, and one we're proud to offer."

    Ethos leverages proprietary technology and predictive and real-time data to remove the friction from the life insurance purchase process, enabling customers to apply for coverage with a 100% digital application that provides customers with decisions in minutes, without lengthy and invasive medical exams. By streamlining the process, Ethos helps more families gain peace of mind and long-term financial stability.

    "Our partnership with Ethos enables people to take control of their long-term health with the same simplicity and ease that Ethos brings to life insurance," said Dugal Bain-Kim, Co-Founder and CEO of Lifeforce. "Together, we're helping people protect what matters most: their future."

    Industry-leading carriers, including Legal & General America, Protective, TruStage™ Financial Group, Inc., John Hancock, and Ameritas Life Insurance Corp., are working with Ethos to enhance the accessibility and affordability of life and insurance and estate planning for millions of families.

    About Ethos

    Ethos is a leading life insurance technology company on a mission to protect families by democratizing access to life insurance and empowering agents at scale. With its robust three-sided technology platform, Ethos is transforming the life insurance experience for consumers, agents, and carriers alike. Ethos offers instant accessible products and a seamless online process that requires no medical exams and just a few health questions; it eliminates traditional barriers, making it easier than ever for everyone to protect their families. Each month, Ethos issues billions in coverage, redefining how life insurance is bought, sold, and underwritten. Learn more at ethos.com.

    About Lifeforce

    Lifeforce is the world's largest longevity medicine platform, empowering adults to add quality years to their lives through at-home biomarker testing, direct access to expert physicians, precision lifestyle coaching, and science-backed therapies. Thousands of members across the United States have already completed more than one million biomarker tests, with 85 percent reporting quality-of-life and health outcomes improvements within six months.

    Learn more at mylifeforce.com.

    Press Contact:

    Allyson Savage

    [email protected]



    Primary Logo

    Get the next $LIFE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIFE

    DatePrice TargetRatingAnalyst
    7/5/2023Outperform → Perform
    Oppenheimer
    11/11/2021$18.00 → $11.00Buy
    HC Wainwright & Co.
    11/11/2021$18.00 → $11.00Action List Buy
    HC Wainwright & Co.
    10/12/2021$22.00Outperform
    RBC Capital
    9/21/2021$19.00Overweight
    Piper Sandler
    9/14/2021$20.00 → $21.00Buy
    Roth Capital
    9/14/2021$14.00 → $20.00Outperform
    Oppenheimer
    9/13/2021$13.00 → $18.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LIFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Denyes Nancy bought $9,276 worth of shares (5,000 units at $1.86), increasing direct ownership by 29% to 22,267 units (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    6/6/24 8:26:55 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coughlin Timothy bought $87,500 worth of shares (50,000 units at $1.75) (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    6/3/24 4:21:12 PM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Broadfoot Jill Marie bought $8,950 worth of shares (5,000 units at $1.79), increasing direct ownership by 22% to 27,960 units (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    6/3/24 8:38:39 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LIFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Denyes Nancy bought $9,276 worth of shares (5,000 units at $1.86), increasing direct ownership by 29% to 22,267 units (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    6/6/24 8:26:55 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coughlin Timothy bought $87,500 worth of shares (50,000 units at $1.75) (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    6/3/24 4:21:12 PM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Broadfoot Jill Marie bought $8,950 worth of shares (5,000 units at $1.79), increasing direct ownership by 22% to 27,960 units (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    6/3/24 8:38:39 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LIFE
    SEC Filings

    View All

    aTyr Pharma Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Other Events, Financial Statements and Exhibits

    8-K - aTYR PHARMA INC (0001339970) (Filer)

    5/29/24 4:03:07 PM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by aTyr Pharma Inc.

    10-Q - aTYR PHARMA INC (0001339970) (Filer)

    5/2/24 4:07:23 PM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - aTYR PHARMA INC (0001339970) (Filer)

    5/2/24 4:04:01 PM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LIFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    aTyr Pharma downgraded by Oppenheimer

    Oppenheimer downgraded aTyr Pharma from Outperform to Perform

    7/5/23 7:41:57 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Buy and set a new price target of $11.00 from $18.00 previously

    11/11/21 6:10:41 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Action List Buy and set a new price target of $11.00 from $18.00 previously

    11/11/21 6:10:41 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LIFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ethos and Lifeforce Team Up to Help Policyholders Live Longer, Healthier Lives

    AUSTIN, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a partnership with Lifeforce, the largest longevity medicine platform. Through this collaboration, Ethos policyholders will be able to gain valuable insights into their own health at affordable prices, starting with a $250 benefit to Lifeforce's Diagnostic offering, that includes at-home biomarker testing, access to board-certified longevity physicians, personalized treatment protocols, and ongoing health coaching. Together, Ethos and Lifeforce aim to help more families safeguard their future - uniting financial protection

    8/13/25 8:00:00 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

    AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. Wheeler to its Board of Directors. Mr. Wheeler, a seasoned executive with deep expertise across insurance, retirement services, and investment banking, joins Ethos' distinguished board, further strengthening Ethos' governance and strategic guidance as the company continues its rapid growth and innovation. Mr. Wheeler brings more than three decades of leadership experience in the financial services industry. He most recently served as Vice Chairman of Athene Holding Ltd. (NYSE:ATH), a leadin

    7/30/25 11:00:00 AM ET
    $EVR
    $LIFE
    $ATH
    Investment Managers
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"

    SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from "LIFE" to "ATYR." Effective at the market open on June 5, 2024, the Company's common stock will trade on the Nasdaq Capital Market under the new symbol "ATYR." "As we advance our lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis and prepare for potential commercialization, the "ATYR" ticker symbol is a strong reflec

    6/3/24 8:00:00 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LIFE
    Leadership Updates

    Live Leadership Updates

    View All

    Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

    AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. Wheeler to its Board of Directors. Mr. Wheeler, a seasoned executive with deep expertise across insurance, retirement services, and investment banking, joins Ethos' distinguished board, further strengthening Ethos' governance and strategic guidance as the company continues its rapid growth and innovation. Mr. Wheeler brings more than three decades of leadership experience in the financial services industry. He most recently served as Vice Chairman of Athene Holding Ltd. (NYSE:ATH), a leadin

    7/30/25 11:00:00 AM ET
    $EVR
    $LIFE
    $ATH
    Investment Managers
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

    SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

    1/18/24 8:00:00 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

    SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human Resources. Ms. Campbell will serve as a member of the company's executive leadership team and oversee all aspects of human resources strategies and functions, including organizational development, talent management and talent acquisition initiatives. "We are delighted to welcome Danielle to aTyr at a pivotal time in the company's journey as we expand our team to support our next phase of growth," said Sanjay S.

    12/24/21 8:02:00 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LIFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/14/24 1:43:55 PM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/13/24 4:30:17 PM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/9/24 8:35:54 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LIFE
    Financials

    Live finance-specific insights

    View All

    aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

    Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

    3/14/24 4:00:00 PM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

    SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7

    2/28/24 8:00:00 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

    SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 9, 2023Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051

    3/2/23 8:00:00 AM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care